Cellebrite DI (CLBT) Capital Expenditures (2020 - 2026)

Cellebrite DI has reported Capital Expenditures for 7 years, with the latest figure at -$3.1 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 14.97% year-over-year to -$3.1 million in Q2 2026; TTM through Jun 2026 was -$13.4 million, a 22.31% decrease from a year earlier, with the FY2025 full-year figure at -$13.2 million, down 54.39% from the prior year.
• Capital Expenditures was -$3.1 million for Q2 2026 at Cellebrite DI, down from -$3.0 million in the prior quarter.
• The five-year high for Capital Expenditures was -$825000.0 in Q2 2023, with the low at -$4.0 million in Q4 2025.
• Average Capital Expenditures over 5 years is -$2.2 million, with a median of -$2.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 53.84% in 2023, then tumbled 151.27% in 2024.
• Over 5 years, Capital Expenditures stood at -$1.4 million in 2022, then slumped by 62.47% to -$2.3 million in 2023, then tumbled by 40.62% to -$3.2 million in 2024, then declined by 24.48% to -$4.0 million in 2025, then gained by 22.45% to -$3.1 million in 2026.
• The last three Capital Expenditures figures came in at -$3.1 million (Q2 2026), -$3.0 million (Q1 2026), and -$4.0 million (Q4 2025), per Business Quant data.